Pharmaceutical sustained-release microsphere for injection and preparation method therefor
Through the improved emulsification preparation method, the problem of insufficient dosage and sudden release of drug sustained-release microsphere preparations in the treatment of schizophrenia was solved, stable release and long-term sustained release were achieved, and the drug experience and treatment effect were improved.
Patent Information
- Application Number
- PCT/CN2024/094248
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-05-20
- Publication Date
- 2024-11-28
AI Technical Summary
The existing drug sustained-release microsphere preparations have problems such as insufficient drug dosage, sudden release, and the inability to quickly reach the treatment concentration in the treatment period. It is difficult to meet the needs of long-term sustained-release, affecting the patient's medication compliance and treatment effect.
The modified emulsification method is used to prepare sustained release microspheres for injection containing drug active ingredients and biocompatible polymer materials. By regulating the ratio of biocompatible polymer materials to drug active ingredients, the amount of surfactant used and the emulsification method, A stable emulsion was formed to prepare microspheres with narrow particle size distribution, high encapsulation rate and small burst release.
It achieves stable release of drugs, quickly reaches the treatment concentration, extends the release time, improves the drug experience and treatment effect, and reduces the occurrence of toxic and side effects.
Smart Images

Figure CN2024094248_28112024_PF_FP_ABST
Abstract
Description
A kind of sustained-release microspheres for injection and preparation method thereof Technical Field
[0001] The present invention relates to the technical field of sustained-release injections, and more particularly to sustained-release microspheres for injection and a preparation method thereof. Background Art
[0002] Sustained-release injections have been a hot research topic in the pharmaceutical field in recent years, particularly in the area of improving existing drug dosage forms to make them more effective clinically. Clinically mature sustained-release injection formulations include liposomes, nanocrystals, implants, sustained-release gels, and sustained-release microspheres.
[0003] Microspheres refer to spheres with a particle size in the micron range and are drug-loaded microspheres. Currently available sustained-release injection products mostly contain drugs that are small molecule compounds or peptide drugs. Microspheres are mainly made of polymer materials into spherical bodies with a particle size of 5 to 100 μm. The drugs can be embedded in the polymer material of the microspheres or enriched on the surface of the microspheres. The stable properties of the polymer material ensure the sustained release effect of the drug, thereby extending the drug release cycle to several weeks or even months. The sustained-release microsphere preparation effectively solves the problem of patient compliance with medication. Only one injection is needed for the drug's efficacy to last for several months. At the same time, the drug maintains a stable concentration in the body, reducing the fluctuation of blood drug concentration caused by dosage and dosing interval, and reducing the occurrence of toxic side effects.
[0004] The first microsphere preparation to be marketed was triptorelin microspheres, a one-month sustained-release formulation successfully developed by Ipsen in France in 1986 for the treatment of prostate cancer, uterine fibroids, breast cancer, and endometriosis. A similar product, leuprorelin microspheres, was subsequently launched in 1995 by Takeda Pharmaceuticals of Japan. In 1998, Novartis developed one-month sustained-release octreotide microspheres for the treatment of acromegaly and neuroendocrine tumors. Due to the specific drug requirements and the matching of the process with polymer materials used in microsphere preparations, as well as the specificity of the long-term medication requirements for these indications, as of 2022, only a dozen drug-loaded sustained-release microsphere products were marketed globally.
[0005] Schizophrenia is a multifactorial, chronic disease requiring long-term medication. Currently available microsphere products for schizophrenia include risperidone microspheres, a two-week extended-release formulation developed and launched by Janssen Pharmaceuticals in 2003. Luye Pharma also launched this product in 2021. Because schizophrenia patients require long-term medication and often experience missed doses and medication resistance, long-acting injections offer a unique advantage in improving patient compliance.
[0006] Currently, the drugs used to treat schizophrenia are mainly small molecule compounds, which are characterized by poor water solubility, and the drugs require a certain dose to achieve a therapeutic effect. Therefore, many drugs are difficult to meet the drug dosage that can be encapsulated in long-acting microspheres for a period of one month or even longer. Janssen Pharmaceuticals' 2-week sustained-release risperidone microspheres for injection (trade name: Hengde) have insufficient drug release in the first three weeks after administration, and need to be supplemented with oral medication to achieve a therapeutic effect, causing inconvenience to patients. Drug burst release refers to a sudden increase in blood drug concentration and a peak after administration, which can cause toxic side effects. Overcoming the burst release phenomenon of microsphere preparations has always been an industry problem. Suppressing the burst release causes insufficient early drug release, which also brings inconvenience to subsequent patients. How to balance the early release of drugs in microsphere preparations and the stable release of drugs that can meet the requirements of one month or even longer, and give patients better therapeutic effects and medication experience is a problem that the pharmaceutical industry needs to solve.
[0007] Brexpiprazole, also known as brexpiprazole and prexpiprazole, was jointly developed by Lundbeck Pharmaceuticals of Denmark and Otsuka Pharmaceuticals of Japan under the trade name Rexulti. It received FDA approval for marketing in the United States in 2015 for the treatment of schizophrenia and major depressive disorder, and entered the European market in 2018. The original product was an oral tablet. Brexpiprazole is an atypical antipsychotic that is a partial agonist at 5-HT1A and dopamine D2 and D3 receptors, and a partial antagonist at 5-HT2A and 5-HT2B receptors and dopamine α-1 and α-2, modulating the brain's monoaminergic neurotransmission system.
[0008] Lurasidone is an atypical antipsychotic drug and an antagonist of dopamine D2, 5-HT2A and 5-HT7 receptors. It is produced by Sumitomo Dainippon Pharma of Japan. It was approved for marketing by the FDA in 2010 and approved for domestic marketing in 2019. The original product is an oral tablet used to treat depressive episodes caused by schizophrenia and bipolar disorder type I.
[0009] Cariprazine is an atypical antipsychotic drug that acts as a partial agonist at both dopamine D2 and D3 receptors, with greater selectivity for D3 receptors and some 5-HT1A receptor agonism. It is used to treat mixed and manic episodes of schizophrenia and bipolar I disorder. Cariprazine, manufactured by AbbVie in the United States, was approved for marketing by the FDA in 2015 and subsequently approved for marketing in the European Union in 2017. It is an oral tablet.
[0010] Brilaroxazine is a partial dopamine agonist that partially agonizes dopamine receptors D2, D3, and D4, partially agonizes serotonin receptors 5-HT1A and 5-HT2A, and antagonizes 5-HT6 and 5-HT7 receptors. Developed by Reviva Pharmaceuticals in the United States, brilaroxazine entered Phase 3 clinical trials in 2022 as a potential treatment for schizophrenia and schizoaffective disorder. (DOI: https: / / doi.org / 10.1038 / s41398-022-01928-8)
[0011] Summary of the Invention
[0012] The inventors discovered that by using a modified emulsification method to prepare an injectable sustained-release microsphere formulation containing a pharmaceutical active ingredient and a biocompatible polymer material, they were able to overcome the problems of insufficient microsphere-encapsulated drug dosage, sudden drug release, and the inability of the drug to quickly reach therapeutic concentrations. This method can also maintain stable blood drug concentrations for a month or even longer. This method requires simultaneous control of the following steps:
[0013] 1. A biocompatible polymer material is dissolved in an organic solvent to form an organic solution, and then a pharmaceutical active ingredient is added to adjust the solubility ratio of the pharmaceutical active ingredient in the organic solution so that a portion of the pharmaceutical active ingredient dissolves in the organic solution and the other portion forms solid particles that are insoluble in the organic solution. The obtained oil phase is dispersed to form a suspension containing the pharmaceutical solid particles.
[0014] 2. Adjust the mass percentage of the biocompatible polymer material and the oil phase to prevent the microspheres from having too many holes, thus avoiding the microspheres being too loose and causing a sudden release of the drug, or the microspheres agglomerating due to excessive concentration. At the same time, adjust the mass percentage of the active pharmaceutical ingredient and the organic solvent to ensure that the amount of the active pharmaceutical ingredient meets the long-term dosage, and control the concentration of solid particles to avoid excessive concentration affecting the microsphere formation during the microsphere preparation process, thereby avoiding the formation of damaged microspheres or irregularly shaped microspheres.
[0015] 3. Adjust the amount of surfactant in the external water phase to control the stable and uniform dispersion of the oil phase droplets to form a stable emulsion;
[0016] 4. Adjust the volume ratio of the oil phase and the external aqueous phase so that different emulsification preparation methods (such as shearing method, homogenization method, etc.) can be applied to optimize the appearance morphology and release behavior of the microsphere preparation.
[0017] Therefore, in response to the above technical problems, the purpose of the present invention is to provide a method for preparing sustained-release microspheres for injection. The purpose of the present invention is also to provide sustained-release microspheres for injection, which have a narrow particle size distribution, high encapsulation rate and small burst release.
[0018] In order to achieve the above objectives, the technical solutions of the present invention are as follows:
[0019] A method for preparing sustained-release microspheres for injection comprises the following steps:
[0020] A) dissolving a biocompatible polymer material in an organic solvent to form an organic solution, adding a pharmaceutical active ingredient and dispersing the pharmaceutical active ingredient in the organic solution to prepare an oil phase;
[0021] B) dissolving a surfactant in water to prepare an external aqueous phase;
[0022] C) mixing the oil phase and the external aqueous phase and emulsifying to obtain a mixed emulsion;
[0023] D) solidifying and drying the mixed emulsion to obtain sustained-release microspheres containing the active pharmaceutical ingredient.
[0024] Preferably, the above-mentioned active pharmaceutical ingredient is partially dissolved in the organic solution and partially forms insoluble solid particles, and the prepared oil phase is a suspension containing the solid pharmaceutical particles.
[0025] Preferably, the mass percentage of the active pharmaceutical ingredient to the organic solvent is 2.7-22.2 wt%.
[0026] Preferably, the mass percentage of the biocompatible polymer material to the oil phase is 9.6-40 wt %.
[0027] Preferably, the mass percentage concentration of the surfactant in the external aqueous phase is 0.1-5.0 wt %.
[0028] Preferably, the ratio of the mass of the organic solvent to the volume of the external aqueous phase is 1:10-1:250 (g / mL).
[0029] Preferably, the organic solvent is dichloromethane.
[0030] Preferably, in step A), the active pharmaceutical ingredient is dispersed in the organic solution using a high shear emulsifier or an ultrasonic device, wherein the rotation speed of the high shear emulsifier can be 10,000 rpm to 20,000 rpm.
[0031] Preferably, the active ingredient of the drug is a small molecule drug, which can be any one of the following: epiriprazole and / or a pharmaceutically acceptable salt thereof, lurasidone and / or a pharmaceutically acceptable salt thereof, cariprazine and / or a pharmaceutically acceptable salt thereof, brelaxaquin and / or a pharmaceutically acceptable salt thereof.
[0032] Preferably, the biocompatible polymer material is one or a mixture of poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), poly(glycolide) (PGA) and poly(vinyl lactone) (PCL).
[0033] Preferably, the surfactant is one or a mixture of polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC), β-cyclodextrin, poloxamer 188, Pluronic F88, Pluronic F127, gelatin, glycine, lysine, histidine, arginine, aspartic acid, glutamic acid, span and Tween.
[0034] Preferably, in step D, the mixed emulsion is solidified into wet microspheres, a protective agent is added, and the microspheres are dried.
[0035] Preferably, the preparation method further comprises the following steps: after obtaining the mixed emulsion, stirring, solidifying, filtering, and washing the mixed emulsion to form wet microspheres, and adding a protective agent to the wet microspheres and then drying them to obtain sustained-release microspheres containing the active pharmaceutical ingredient.
[0036] Preferably, the protective agent is one or a mixture of polyethylene glycol (PEG), gelatin, glycerol, mannitol, sucrose, trehalose, lactose, glucose, propylene glycol, sorbitol, zinc chloride, zinc sulfate, zinc acetate and human serum albumin.
[0037] Preferably, other auxiliary materials are added at the same time as the protective agent, and the other auxiliary materials are surfactants and / or excipients.
[0038] As another aspect of the present invention, there is also provided a sustained-release microsphere for injection prepared according to any one of the above methods.
[0039] According to the present invention, in step A) of the method for preparing the sustained-release injectable microspheres of the present invention, the oil phase can be a suspension containing solid drug particles. The active pharmaceutical ingredient can be eriprazole or a pharmaceutically acceptable salt thereof; lurasidone or a pharmaceutically acceptable salt thereof; cariprazine or a pharmaceutically acceptable salt thereof; or brelasarzine or a pharmaceutically acceptable salt thereof.
[0040] In an embodiment according to the present invention, the mass percentage of the active pharmaceutical ingredient to the organic solvent is 2.7-22.2 wt %, and the calculation formula is: mass percentage of the active pharmaceutical ingredient to the organic solvent = mass of the active pharmaceutical ingredient / mass of the organic solvent * 100%.
[0041] In a preferred embodiment according to the present invention, the biocompatible polymer material is poly(lactic acid-co-glycolic acid) (PLGA), and the molar ratio of glycolide (LA) to lactide (GA) in PLGA is 50:50 to 85:15, the molecular weight is 5 to 100 kilodaltons, and the viscosity characteristic is 0.1 to 0.6 dL / g; wherein, the type and molecular weight of PLGA include but are not limited to: PLGA (LA:GA is 50:50; Mw 10,000 to 25,000 daltons), PLGA (LA:GA is 55:45; Mw 15,000 to 55,000 daltons), PLGA (LA:GA is 65:35; Mw 15,000 to 55,000 daltons), PLGA (LA:GA is 75:25; Mw 10,000 to 25,000 daltons), PLGA (LA:GA is 50:50; Mw 20,000 to 80,000 Daltons), PLGA (LA:GA of 75:25; Mw 30,000 to 90,000 Daltons), or PLGA (LA:GA of 85:15; Mw 55,000 to 85,000 Daltons).
[0042] In another preferred embodiment according to the present invention, the biocompatible polymer material is polylactic acid (PLA) with a molecular weight of 10 to 55 kilodaltons and a viscosity characteristic of 0.1 to 0.6 dL / g, such as PLA (Mw 10,000 to 25,000 Daltons) and PLA (Mw 15,000 to 55,000 Daltons).
[0043] In the present invention, the mass percentage of the biocompatible polymer material to the oil phase is calculated as follows: mass percentage of the biocompatible polymer material to the oil phase = mass of the biocompatible polymer material / (mass of the biocompatible polymer material + mass of the organic solvent + mass of the active pharmaceutical ingredient) * 100%.
[0044] In an embodiment according to the present invention, the mass percentage of PLGA to oil phase is preferably 9.6-40 wt %.
[0045] According to the present invention, in step B) of the method for preparing sustained-release microspheres for injection, the surfactant can be selected from one or a mixture of polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC), β-cyclodextrin, poloxamer 188, Pluronic F88, Pluronic F127, gelatin, glycine, lysine, histidine, arginine, aspartic acid, glutamic acid, span and Tween; preferably, the surfactant is PVA, PVP or a combination thereof, and particularly preferably, the surfactant is PVA.
[0046] In the present invention, the mass percentage concentration of the surfactant in the external water phase is calculated as follows: mass percentage concentration of the surfactant in the external water phase = mass of the surfactant / (mass of the surfactant+mass of water)*100%.
[0047] In an embodiment according to the present invention, the mass percentage concentration of the surfactant in the external aqueous phase is preferably 0.1-5 wt %.
[0048] According to the present invention, in step C) of the method for preparing sustained-release microspheres for injection, the emulsification preparation method can be a high-shear emulsifier, a high-pressure homogenizer, a static mixer, or a combination thereof. The high-shear emulsifier can have a rotation speed of 2000 rpm to 20,000 rpm, and a shear time of 0.5 min to 10 min; the high-pressure homogenizer can have a pressure of 100 bar to 800 bar, and the number of continuous homogenizations can be 2 to 6 times; the static mixer can have a diameter of ND6 to DN25, and a mixing flow rate of 1 L / min to 20 L / min.
[0049] In a preferred embodiment of the present invention, in step C) of the method for preparing sustained-release microspheres for injection, the ratio of the mass of the organic solvent to the volume of the external aqueous phase is preferably 1:10-1:250, expressed in g / mL.
[0050] According to the present invention, in step D) of the method for preparing sustained-release microspheres for injection, if stirring is performed, the stirring speed may be 1500-5000 rpm, and the stirring time may be 15-120 min.
[0051] According to the present invention, in step D) of the method for preparing sustained-release microspheres for injection, the curing temperature may be 5° C. to 45° C., and the curing time may be 2 h to 24 h.
[0052] According to the present invention, a protective agent is added to the wet microspheres obtained by solidifying the mixed emulsion in step D) of the method for preparing sustained-release microspheres for injection. The protective agent is an excipient added to the wet microspheres to increase the fluidity and dispersibility of the dry microsphere powder obtained according to step D), regulate the osmotic pressure of the microspheres, and protect the stability and activity of the small molecule drug. The protective agent can be selected from one or a mixture of polyethylene glycol (PEG), gelatin, glycerol, mannitol, sucrose, trehalose, lactose, glucose, propylene glycol, sorbitol, zinc chloride, zinc sulfate, zinc acetate, and human serum albumin; preferably, the protective agent is mannitol.
[0053] The present invention also provides a sustained-release microsphere for injection, comprising the sustained-release microsphere for injection prepared according to the above method, wherein the sustained-release microsphere for injection comprises active ingredients of epiriprazole, lurasidone, cariprazine, and brelatin, a biocompatible polymer carrier material, and other pharmaceutically acceptable excipients.
[0054] The pharmaceutically acceptable other auxiliary materials include surfactants and excipients. In addition, the pharmaceutically acceptable other auxiliary materials may also include protective agents.
[0055] The sustained-release microsphere preparation for injection has a sustained-release period of about 30 to 45 days, i.e., about four to six weeks, for example, about four weeks, five weeks, six weeks, or about one month, or one and a half months. The difference between "about" and "approximately" is "(±1 to 6 days)."
[0056] According to the present invention, the sustained-release microspheres for injection prepared by the above method have a particle size (D50) of 5-200 μm, and not only the particle size distribution of the microspheres is narrow (SPAN value (SPAN = (D 90 -D 10 ) / D 50 ) is less than 3), and the encapsulation efficiency is significantly improved and the burst release rate is reduced. Furthermore, compared to existing daily oral tablets, the injectable sustained-release microsphere preparation containing the pharmaceutical active ingredient according to the present invention provides a completely new mode of administration, realizing the characteristics of long-acting sustained-release microspheres. Ideally, it can achieve a sustained release of the drug for 4-6 weeks, providing a more optimal route of administration for patients with poor gastrointestinal absorption, while also reducing the occurrence of drug tolerance and toxic side effects.
[0057] The technical solution of the present invention has the following beneficial effects:
[0058] The preparation method of the present invention is relatively simple and easy to implement, can be used for industrial operation, and has universal applicability; at the same time, according to the preparation method, a sustained-release microsphere preparation for injection with a narrow microsphere particle size distribution is prepared, and its encapsulation rate is significantly improved, the burst release rate is reduced, the release time is prolonged, and the therapeutic concentration can be quickly reached.
[0059] 1) By controlling the ratio of the active pharmaceutical ingredient and the biocompatible polymer material in the organic solvent, the mass percentage concentration of the surfactant in the external aqueous phase, and the ratio of the mass of the organic solvent to the volume of the external aqueous phase in the preparation method, a microsphere preparation containing the active pharmaceutical ingredient is obtained by emulsification, and the 24-hour in vitro burst release rate is less than 5%, and the encapsulation efficiency is greater than 80% or even greater than 85%. The preparation method is simple and can be applied to the industrialization of the microsphere preparation production process.
[0060] 2) The present invention provides a novel microsphere preparation method in which a portion of the drug powder is dissolved in an organic solution, while the remaining portion is dispersed in the organic solution in the form of particles, resulting in an oil phase suspension containing solid drug particles. The drug dissolved in the oil phase is dispersed on the surface of the microspheres, enabling rapid release of the drug, allowing the drug to quickly reach therapeutic concentrations. The suspended particles increase the microspheres' encapsulation capacity, increasing the drug loading capacity and ensuring sufficient drug for a long-lasting dose. Furthermore, this portion of the drug release is slightly slower, extending its release time in the body.
[0061] 3) The present invention also provides a method for adding a protective agent to the wet microspheres, which increases the fluidity and dispersibility of the microsphere dry powder, regulates the osmotic pressure of the microspheres, and protects the stability and activity of the drug.
[0062] 4) The sustained-release microsphere preparation for injection prepared according to the preparation method of the present invention has a narrow particle size distribution and can release the active pharmaceutical ingredient for approximately four to six weeks. Furthermore, the small molecule microsphere preparation prepared by the present invention can accurately maintain drug concentration in the blood of animals. The small molecule sustained-release microspheres can effectively maintain blood drug concentration for 4-6 weeks without significant fluctuations in blood drug concentration, thereby better avoiding the occurrence of toxic side effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] FIG1 is a scanning electron micrograph of sustained-release microspheres for injection prepared according to Example 3 of the present invention.
[0064] FIG2 is a scanning electron micrograph of sustained-release microspheres for injection prepared according to Example 8 of the present invention.
[0065] FIG3 is a scanning electron micrograph of sustained-release microspheres for injection prepared according to Example 15 of the present invention.
[0066] FIG4 is a scanning electron micrograph of sustained-release microspheres for injection prepared according to Example 19 of the present invention.
[0067] FIG5 is an in vitro release-time curve of sustained-release microspheres for injection prepared according to Examples 3, 8, 15, and 19 of the present invention.
[0068] FIG6 is the in vivo pharmacokinetic curves of sustained-release microspheres for injection prepared according to Examples 2, 8, 15, and 20 of the present invention. DETAILED DESCRIPTION
[0069] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but the present invention should not be limited to the specific embodiments disclosed below.
[0070] In the following examples, small molecule microsphere preparations for injection will be exemplarily prepared by the method for preparing small molecule microspheres for injection according to the present invention.
[0071] The active ingredient of the present invention, ipilimumab, may be a compound having a molecular formula of C 25 H 27 N3O2S, an epiriprazole compound with a molar mass of 433.57 g / mol (DOI:10.1111 / pcn.13438).
[0072] The active ingredient of the lurasidone in the present invention may be a compound having the molecular formula C 28 H 36 N4O2S, a lurasidone compound with a molar mass of 492.68 g / mol, or a compound with a molecular formula of C 28 H 37 ClN4O2S, lurasidone hydrochloride with a molar mass of 529.14 g / mol (DOI:10.1124 / jpet.110.167346).
[0073] The active pharmaceutical ingredient of the present invention may be cariprazine, which has the molecular formula C 21 H 32 Cl2N4O2, cariprazine compound with a molar mass of 427.41 g / mol, or a molecular formula of C 21 H 33 Cl3N4O2, cariprazine hydrochloride with a molar mass of 463.87 g / mol (DOI:10.1007 / s12325-021-01797-5).
[0074] The active pharmaceutical ingredient of the present invention may be a pharmaceutically active ingredient having a molecular formula of C 22 H 25 Cl2N3O3, brelasaqin compound with a molar mass of 450.36 g / mol, CAS number 1239729-06-6 (DOI:10.2147 / JEP.S259317).
[0075] Unless otherwise specified, the methods used in the following examples are commonly used by those skilled in the art.
[0076] Example 1 (epiprazole)
[0077] 0.56 g of epiriprazole was added to a mixed solution of 4.16 g of dichloromethane and 2.24 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 12,000 rpm to form an oil phase. 1,000 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as an external aqueous phase. The oil phase and the external aqueous phase were mixed using a high-shear emulsifier at a shear rate of 3,000 rpm for 4 minutes to form an emulsion. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed with distilled water multiple times, collected, added with a protective agent, and freeze-dried to obtain an epiriprazole sustained-release microsphere preparation.
[0078] The average particle size (D50) of the microspheres of the preparation was 45 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.22. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 98% and 90%.
[0079] Example 2 (epiprazole)
[0080] 1.68 g of epiriprazole was added to a mixed solution of 28.08 g of dichloromethane and 15.12 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 3,000 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 minute. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and the mixture was freeze-dried to obtain an epiriprazole sustained-release microsphere preparation.
[0081] The average particle size (D50) of the microspheres of the preparation was 49 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.33. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 91% and 88%.
[0082] Example 3 (epiprazole)
[0083] 2.0 g of epiriprazole was added to a mixed solution of 11.14 g of dichloromethane and 6.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to form an oil phase. 1600 mL of a 0.1 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as an external aqueous phase. The oil phase and the external aqueous phase were mixed using a high-shear emulsifier at a shear rate of 3,000 rpm for 4 minutes to form an emulsion. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed with distilled water multiple times, collected, added with a protective agent, and freeze-dried to obtain an epiriprazole sustained-release microsphere preparation.
[0084] The average particle size (D50) of the microspheres of the preparation was 42 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.12. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 96% and 91%.
[0085] Example 4 (epiprazole)
[0086] 0.35 g of epiriprazole was added to a mixed solution of 9.0 g of dichloromethane and 1.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 100 mL of a 5.0 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 minute. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and the mixture was freeze-dried to obtain an epiriprazole sustained-release microsphere preparation.
[0087] The average particle size (D50) of the microspheres of the preparation was 44 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.21. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency was 94% and the yield was 89%.
[0088] Example 5 (epiprazole)
[0089] 1.12 g of epiriprazole was added to a mixed solution of 6.72 g of dichloromethane and 4.48 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.19 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 1,000 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 minute. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain an epiriprazole sustained-release microsphere preparation.
[0090] The average particle size (D50) of the microspheres of the preparation was 45 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.32. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 95% and 93%.
[0091] Example 6 (epiprazole)
[0092] 1.49 g of epiriprazole was added to a mixed solution of 5.23 g of dichloromethane and 2.24 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.36 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to form the oil phase. 500 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 minute. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain an epiriprazole sustained-release microsphere preparation.
[0093] The average particle size (D50) of the microspheres of the preparation was 51 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.37. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 92% and 91%.
[0094] Example 7 (Lurasidone)
[0095] 1.5 g of lurasidone hydrochloride was added to a mixed solution of 15.5 g of dichloromethane and 2.7 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 800 mL of a 0.1 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a high-shear emulsifier at a shear rate of 3,000 rpm for 4 minutes to form an emulsion. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain a lurasidone sustained-release microsphere preparation.
[0096] The average particle size (D50) of the microspheres of the preparation was 41 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.23. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 97% and 92%.
[0097] Example 8 (Lurasidone)
[0098] 4.0 g of lurasidone hydrochloride was added to a mixed solution of 31.64 g of dichloromethane and 12.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.19 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 500 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain a lurasidone sustained-release microsphere preparation.
[0099] The average particle size (D50) of the microspheres of the preparation was 46 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.39. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 92% and 89%.
[0100] Example 9 (Lurasidone)
[0101] 1.8 g of lurasidone hydrochloride was added to a mixed solution of 31.20 g of dichloromethane and 10.4 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 800 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification was completed, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain a lurasidone sustained-release microsphere preparation.
[0102] The average particle size (D50) of the microspheres of the preparation was 45 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.33. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 91% and 89%.
[0103] Example 10 (Lurasidone)
[0104] 0.6 g of lurasidone hydrochloride was added to a mixed solution of 4.50 g of dichloromethane and 2.8 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 800 mL of a 4.5 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification was completed, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain a lurasidone sustained-release microsphere preparation.
[0105] The average particle size (D50) of the microspheres of the preparation was 42 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.26. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 92% and 90%.
[0106] Example 11 (Lurasidone)
[0107] 1.2 g of lurasidone hydrochloride was added to a mixed solution of 8.40 g of dichloromethane and 2.8 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 800 mL of a 0.1 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After solidification, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain a lurasidone sustained-release microsphere preparation.
[0108] The average particle size (D50) of the microspheres of the preparation was 45 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.28. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 97% and 92%.
[0109] Example 12 (Lurasidone)
[0110] 4.8 g of lurasidone hydrochloride was added to a mixed solution of 21.61 g of dichloromethane and 7.2 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.36 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 800 mL of a 0.1 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification was completed, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain a lurasidone sustained-release microsphere preparation.
[0111] The average particle size (D50) of the microspheres of the preparation was 48 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.21. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 96% and 94%.
[0112] Example 13 (Cariprazine)
[0113] 0.46 g of cariprazine was added to a mixed solution of 7.69 g of dichloromethane and 4.14 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and dispersed by a high shear emulsifier at a shear rate of 15,000 rpm as the oil phase; 500 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 0.25 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed by a high shear emulsifier at a shear rate of 3,000 rpm for 4 minutes to form an emulsion; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; after the solidification was completed, the emulsion was filtered and collected by a filter, and washed with distilled water several times, then collected, added with a protective agent, and freeze-dried to obtain a cariprazine sustained-release microsphere preparation.
[0114] The average particle size (D50) of the microspheres of the preparation was 46 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.28. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 87% and 86%.
[0115] Example 14 (Cariprazine)
[0116] 1.0 g of cariprazine was added to a mixed solution of 13.5 g of dichloromethane and 9.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.19 dL / g), and dispersed by a high shear emulsifier at a shear rate of 15,000 rpm as the oil phase; 200 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 4.0 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed by a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; after the solidification was completed, the emulsion was filtered and collected by a filter, and washed with distilled water several times, then collected, added with a protective agent, and freeze-dried to obtain a cariprazine sustained-release microsphere preparation.
[0117] The average particle size (D50) of the microspheres of the preparation was 46 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.39. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 86% and 89%.
[0118] Example 15 (Cariprazine)
[0119] 2.0 g of cariprazine was added to a mixed solution of 14.86 g of dichloromethane and 8.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and dispersed by a high shear emulsifier at a shear rate of 15,000 rpm as the oil phase; 200 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 4.0 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed by a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; after the solidification was completed, the emulsion was filtered and collected by a filter, and washed with distilled water several times, then collected, added with a protective agent, and freeze-dried to obtain a cariprazine sustained-release microsphere preparation.
[0120] The average particle size (D50) of the microspheres of the preparation was 42 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.26. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 96% and 89%.
[0121] Example 16 (Cariprazine)
[0122] 2.0 g of cariprazine was added to a mixed solution of 72.0 g of dichloromethane and 8.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.19 dL / g), and dispersed by a high shear emulsifier at a shear rate of 15,000 rpm as the oil phase; 3000 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 0.25 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed by a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; after the solidification was completed, the emulsion was filtered and collected by a filter, and washed with distilled water several times, then collected, added with a protective agent, and freeze-dried to obtain a cariprazine sustained-release microsphere preparation.
[0123] The average particle size (D50) of the microspheres of the preparation was 47 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.29. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 90% and 93%.
[0124] Example 17 (Cariprazine)
[0125] 2.0 g of cariprazine was added to a mixed solution of 54.0 g of dichloromethane and 6.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.50 dL / g), and dispersed by a high shear emulsifier at a shear rate of 15,000 rpm as the oil phase; 1500 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 0.25 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed by a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; after the solidification was completed, the emulsion was filtered and collected by a filter, and washed with distilled water several times, then collected, added with a protective agent, and freeze-dried to obtain a cariprazine sustained-release microsphere preparation.
[0126] The average particle size (D50) of the microspheres of the preparation was 45 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.22. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency was 84% and the yield was 91%.
[0127] Example 18 (Cariprazine)
[0128] 3.0 g of cariprazine was added to a mixed solution of 12.0 g of dichloromethane and 8.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.19 dL / g), and dispersed by a high shear emulsifier at a shear rate of 15,000 rpm as the oil phase; 2400 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 0.25 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed by a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; after the solidification was completed, the emulsion was filtered and collected by a filter, and washed with distilled water several times, then collected, added with a protective agent, and freeze-dried to obtain a cariprazine sustained-release microsphere preparation.
[0129] The average particle size (D50) of the microspheres of the preparation was 43 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.34. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 85% and 91%.
[0130] Example 19 (Brelasazine)
[0131] 0.62 g of brelasarzine was added to a mixed solution of 5.77 g of dichloromethane and 2.45 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to form the oil phase. 1400 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a high-shear emulsifier at a shear rate of 3,000 rpm for 4 minutes to form an emulsion. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed with distilled water several times, and then collected. After adding a protective agent, the microspheres were freeze-dried to obtain a brelasarzine sustained-release microsphere preparation.
[0132] The average particle size (D50) of the microspheres of the preparation was 46 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.34. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 89% and 88%.
[0133] Example 20 (Brelasazine)
[0134] 1.82 g of brelasarzine was added to a mixed solution of 29.8 g of dichloromethane and 16.34 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 3,000 mL of a 4.5 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After solidification, the emulsion was filtered and collected using a filter to obtain the microspheres, which were washed multiple times with distilled water, then collected, added with a protective agent, and freeze-dried to obtain a brelasarzine sustained-release microsphere preparation.
[0135] The average particle size (D50) of the microspheres of the preparation was 44 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.32. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 92% and 89%.
[0136] Example 21 (Brelasazine)
[0137] 3.0 g of brelasarzine was added to a mixed solution of 15.25 g of dichloromethane and 8.4 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 1600 mL of a 0.1 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After solidification, the emulsion was filtered and collected using a filter to obtain the microspheres, which were washed multiple times with distilled water, then collected, added with a protective agent, and freeze-dried to obtain a brelasarzine sustained-release microsphere preparation.
[0138] The average particle size (D50) of the microspheres of the preparation was 45 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.27. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency was 94% and the yield was 88%.
[0139] Example 22 (Brelasazine)
[0140] 0.4 g of brelasarzine was added to a mixed solution of 9.0 g of dichloromethane and 1.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 120 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification was completed, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. After adding a protective agent, the mixture was freeze-dried to obtain a brelasarzine sustained-release microsphere preparation.
[0141] The average particle size (D50) of the microspheres of the preparation was 49 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.38. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 91% and 86%.
[0142] Example 23 (Brelasazine)
[0143] 1.08 g of brelasarzine was added to a mixed solution of 6.72 g of dichloromethane and 4.6 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.19 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 1,000 mL of a 0.20 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After solidification, the emulsion was filtered and collected using a filter to obtain the microspheres, which were washed multiple times with distilled water, then collected, added with a protective agent, and freeze-dried to obtain a brelasarzine sustained-release microsphere preparation.
[0144] The average particle size (D50) of the microspheres of the preparation was 42 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.18. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 96% and 91%.
[0145] Example 24 (Brelasazine)
[0146] 1.64 g of brelasarzine was added to a mixed solution of 7.0 g of dichloromethane and 2.45 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.36 dL / g), and the mixture was dispersed using a high-shear emulsifier at a shear rate of 15,000 rpm to serve as the oil phase. 500 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification was completed, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. After adding a protective agent, the mixture was freeze-dried to obtain a brelasarzine sustained-release microsphere preparation.
[0147] The average particle size (D50) of the microspheres of the preparation was 44 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.28. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 94% and 91%.
[0148] Test Example 1: In vitro release rate test
[0149] In this test example 1, the sustained-release microsphere preparations for injection of epiriprazole, lurasidone, cariprazine, and brelaxaquin prepared in Examples 1-24 above were used as examples to conduct an in vitro release rate test. The specific method is as follows:
[0150] 20 mg of the sustained-release microsphere preparations for injection prepared in Examples 1-24 were accurately weighed and added to a 15 mL centrifuge tube. 15 mL of preheated release medium was added, and the release medium was 0.05 M pH 7.4 phosphate buffer. The tube was then placed in a 37°C incubator. 1 mL of the sample was taken at the corresponding time point and 1 mL of the corresponding release medium was added. Figure 5 (for Examples 3, 8, 15, and 19) exemplarily shows the cumulative release rate curve obtained from the test. For the 24-hour burst release rate, release duration, and total cumulative release rate of Examples 1-24 obtained from the test, see Table 1:
[0151] Table 1: 24-hour burst release rate, in vitro release duration and total cumulative release rate of Examples 1-24 obtained from the test:
[0152] Combining the results in Table 1 and Figure 5, it can be seen that the sustained-release microsphere preparation for injection prepared according to the method of the present invention has a stable release performance; based on the composition of the biocompatible polymer carrier contained therein, the preparation can continuously release the drug for more than about four weeks, and the drug is basically completely released (at least about 85%) without the phenomenon of sudden drug release, thus meeting the requirements of sustained release.
[0153] Test Example 2: Single-dose pharmacokinetic study in rats
[0154] In this Test Example 2, pharmacokinetic experiments were conducted in rats using the sustained-release microsphere preparations for injection of epiprazole, lurasidone, cariprazine, and brelasarquin prepared in Examples 1 to 24. The specific method is as follows:
[0155] Adult male SD rats weighing 300-450 g were used as study subjects and administered intramuscularly. Sustained-release microsphere formulations for injection of epiriprazole, lurasidone, cariprazine, and brelaxaquin, prepared according to Examples 1-24 of the present invention, were administered at doses of 15 mg / kg (Example 2), 35 mg / kg (Example 8), 20 mg / kg (Example 15), and 15 mg / kg (Example 20), respectively. At specific times after administration, 0.3 mL of blood was collected from the jugular vein and transferred to a centrifuge tube containing EDTA-K2 anticoagulant. The tube was inverted 5-10 times to thoroughly mix the anticoagulant and blood, and then temporarily stored at room temperature on wet ice. Plasma samples were then separated and stored frozen at -80°C after centrifugation at 4000 rpm for 15 minutes in a high-speed refrigerated centrifuge at 4°C. The plasma drug concentrations (ng / mL) in the plasma samples were determined at each time point using LC / MS. The in vivo plasma drug concentration-time curves are shown in Figure 6.
[0156] As can be seen from Figure 6, the sustained-release microsphere preparation for injection prepared according to the method of the present invention has stable release in rats, and the drug concentration can be maintained in a stable range within one month without large fluctuations. This shows that in the sustained-release microsphere preparation for injection according to the present invention, the selection of the preparation method and the selection of biocompatible polymer materials make the drug stable during the sustained release process without obvious drug degradation.
[0157] Comparative Example of Eripiprazole
[0158] Comparative Example 1: Comparison of properties of the active ingredient Eripiprazole in the oil phase
[0159] In Comparative Example 1, the properties of the active pharmaceutical ingredient of epiriprazole suspended in an organic solvent were compared based on Examples 1-6 described above. The active pharmaceutical ingredient must be uniformly dispersed in the solution to produce a microsphere formulation with a sustained, smooth drug release and minimal burst release. Comparative Formulations 1 and 2 were prepared using the microsphere preparation process for complete dissolution of the active pharmaceutical ingredient according to the process parameters of Examples 2 and 5, respectively.
[0160] The methods for preparing the above-mentioned comparative preparations 1 and 2 are based on the preparation method of completely dissolving the active pharmaceutical ingredient. The main difference is that the active ingredient of irinotecan and the biocompatible polymer material are completely dissolved in the organic solvent first and then, and no dispersion is performed during the dissolution process. The methods for preparing the above-mentioned comparative preparations 1 and 2 are as follows:
[0161] Preparation of Comparative Formulation 1
[0162] 1.68 g of epiriprazole was added to 28.08 g of dichloromethane, and after dissolution, 15.12 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g) was added to the mixture as the oil phase; 3000 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 minute; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; the emulsion after solidification was filtered and collected using a filter, and the microspheres were washed multiple times with distilled water, then collected, added with a protective agent, and freeze-dried to obtain an epiriprazole sustained-release microsphere preparation.
[0163] The average particle size (D50) of the microspheres of the preparation was 52 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.42. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency was 78% and the yield was 86%.
[0164] Preparation of Comparative Formulation 2
[0165] 1.12 g of epiriprazole was added to 6.72 g of dichloromethane, and after dissolution, 4.48 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.19 dL / g) was added to the mixture as the oil phase; 1000 mL of a 0.25 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 minute; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; the emulsion after solidification was filtered and collected using a filter, and the microspheres were washed multiple times with distilled water, then collected, added with a protective agent, and freeze-dried to obtain an epiriprazole sustained-release microsphere preparation.
[0166] The average particle size (D50) of the microspheres of the preparation was 56 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.41. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency was 68% and the yield was 83%.
[0167] Furthermore, in vitro release testing of Comparative Formulations 1 and 2 was conducted using the in vitro release testing method described in Test Example 1 of the present invention. The total cumulative release rate of Comparative Formulation 1 reached 93% after 21 days, failing to meet the one-month sustained release requirement. Comparative Formulation 2 not only had a low encapsulation efficiency but also exhibited a large number of broken spheres, resulting in a 24-hour burst release rate of 12%.
[0168] Lurasidone Comparative Example
[0169] Comparative Example 2: Comparison of properties of lurasidone active ingredient in oil phase
[0170] In Comparative Example 2, the properties of lurasidone suspensions in organic solvents were compared based on Examples 7-12 described above. The active pharmaceutical ingredient must be uniformly dispersed in the solution to produce microsphere formulations with sustained, smooth drug release and minimal burst release. Comparative Formulations 3 and 4 were prepared using conventional microsphere preparation processes according to the process parameters of Examples 7 and 12, respectively.
[0171] The methods for preparing the above-mentioned comparative preparations 3 and 4 were carried out according to conventional preparation methods, with the main difference being that the lurasidone active ingredient and the biocompatible polymer material were dissolved in the organic solvent sequentially and no dispersion was performed during the dissolution process. The methods for preparing the above-mentioned comparative preparations 3 and 4 are as follows:
[0172] Preparation of Comparative Formulation 3
[0173] 1.5 g of lurasidone hydrochloride was added to 15.5 g of dichloromethane. After dissolution, 2.7 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g) was added to the mixture as the oil phase. 800 mL of a 0.1 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a high-shear emulsifier at a shear rate of 3000 rpm and an emulsification time of 4 minutes to form an emulsion. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain a lurasidone sustained-release microsphere preparation.
[0174] The average particle size (D50) of the microspheres of the preparation was 59 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.51. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency was 64% and the yield was 78%.
[0175] Preparation of Comparative Formulation 4
[0176] 4.8 g of lurasidone hydrochloride was added to 21.61 g of dichloromethane. After dissolution, 7.2 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.36 dL / g) was added to the mixture as the oil phase. 800 mL of a 0.1 wt% aqueous solution of polyvinyl alcohol (PVA) for injection was prepared as the external aqueous phase. The oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min. The organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours. After the solidification was completed, the microspheres were filtered and collected using a filter, washed multiple times with distilled water, and then collected. A protective agent was added and freeze-dried to obtain a lurasidone sustained-release microsphere preparation.
[0177] The average particle size (D50) of the microspheres of the preparation was 64 μm. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency was 56%, with a large number of broken microspheres.
[0178] Comparative Formulations 3 and 4 were tested in vitro for release according to the in vitro release test method described in Test Example 1 of the present invention. The 24-hour burst release rates of Comparative Formulations 3 and 4 reached 18% and 15%, respectively. Furthermore, the total cumulative release rate of Comparative Formulation 3 exceeded 95% after 21 days, failing to meet the one-month sustained release requirement.
[0179] Cariprazine Comparative Example
[0180] Comparative Example 3: Comparison of properties of cariprazine active ingredient in oil phase
[0181] In Comparative Example 3, the properties of cariprazine's active pharmaceutical ingredient suspension in an organic solvent were compared based on Examples 13-18 described above. The active pharmaceutical ingredient must be uniformly dispersed in the solution to produce a microsphere formulation with sustained, smooth drug release and minimal burst release. Comparative Formulations 5 and 6 were prepared using conventional microsphere preparation processes according to the process parameters of Examples 13 and 18, respectively.
[0182] The methods for preparing the above-mentioned comparative preparations 5 and 6 were carried out according to conventional preparation methods, with the main difference being that the cariprazine active ingredient and the biocompatible polymer material were dissolved in the organic solvent sequentially and no dispersion was performed during the dissolution process. The methods for preparing the above-mentioned comparative preparations 5 and 6 are as follows:
[0183] Preparation of Comparative Formulation 5
[0184] 0.46 g of cariprazine was added to 7.69 g of dichloromethane, and after dissolution, 4.14 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g) was added to the mixture as the oil phase; 500 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 0.25 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed by a high shear emulsifier at a shear rate of 3000 rpm and an emulsification time of 4 min, and the mixture was uniformly mixed to form an emulsion; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; after the solidification was completed, the emulsion was filtered and collected using a filter to obtain the microspheres, and washed with distilled water several times, then collected, added with a protective agent, and freeze-dried to obtain a cariprazine sustained-release microsphere preparation.
[0185] The average particle size (D50) of the microspheres of the preparation was 56 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.52. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency was 58% and the yield was 77%.
[0186] Preparation of Comparative Formulation 6
[0187] 3.0 g of cariprazine was added to 12.0 g of dichloromethane, and after dissolution, 8.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.19 dL / g) was added to the mixture as the oil phase; 2400 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 0.25 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed by a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; after the solidification was completed, the emulsion was filtered and collected using a filter to obtain the microspheres, and washed with distilled water several times, then collected, added with a protective agent, and freeze-dried to obtain a cariprazine sustained-release microsphere preparation.
[0188] The average particle size (D50) of the microspheres of the preparation was 66 μm. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency was 47%.
[0189] Comparative Formulations 5 and 6 were subjected to in vitro release testing according to the in vitro release testing method described in Test Example 1 of the present invention. The 24-hour burst release rates of both Comparative Formulations 5 and 6 exceeded 20%. Furthermore, the total cumulative release rate of Comparative Formulation 3 exceeded 95% after 21 days, failing to meet the one-month sustained release requirement.
[0190] Comparative Example of Bresalazine
[0191] Comparative Example 4: Comparison of properties of brexalazone active ingredient in oil phase
[0192] In Comparative Example 3, the properties of brexalazone as a pharmaceutical active ingredient suspended in an organic solvent were compared based on Examples 19-24 of the present invention. The pharmaceutical active ingredient must be uniformly dispersed in the solution to produce a microsphere formulation with a sustained, smooth drug release and minimal burst release. Comparative Formulations 7 and 8 were prepared using a conventional microsphere preparation process according to the process parameters of Examples 22 and 23, respectively.
[0193] Comparative Preparations 7 and 8 were prepared according to conventional methods, with the primary difference being that the brexalatin active ingredient and the biocompatible polymer were dissolved in the organic solvent sequentially, without dispersion during the dissolution process. The specific methods for preparing Comparative Preparations 7 and 8 are as follows:
[0194] Preparation of Comparative Formulation 7
[0195] 0.4 g of brelasarzine was added to 9.0 g of dichloromethane, and after dissolution, 1.0 g of PLGA (wherein the molar ratio of glycolide to lactide was 50:50 and the intrinsic viscosity was 0.24 dL / g) was added to the mixture as the oil phase; 120 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 0.25 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25° C., and the microspheres were volatilized and solidified for 6 hours; the emulsion after solidification was filtered and collected using a filter, and the microspheres were washed multiple times with distilled water, then collected, added with a protective agent, and freeze-dried to obtain a brelasarzine sustained-release microsphere preparation.
[0196] The average particle size (D50) of the microspheres of the preparation was 58 μm, and the SPAN value (SPAN=(D90-D10) / D50) was 1.57. The obtained sustained-release microspheres were quantitatively determined by HPLC, and the encapsulation efficiency and yield were 68% and 69%.
[0197] Preparation of Comparative Formulation 8
[0198] 1.08 g of brelasarzine was added to 6.72 g of dichloromethane, and after dissolution, 4.6 g of PLGA (wherein the molar ratio of glycolide to lactide was 75:25 and the intrinsic viscosity was 0.19 dL / g) was added to the mixture as the oil phase; 1000 mL of a polyvinyl alcohol (PVA) aqueous solution for injection with a concentration of 0.20 wt% was prepared as the external aqueous phase; the oil phase and the external aqueous phase were mixed using a static mixer at a flow rate of 6 L / min and a mixing and emulsification time of 1 min; the organic solvent was removed from the emulsion at a stirring speed of 300 rpm and a temperature of 25°C, and the microspheres were volatilized and solidified for 6 hours; after the solidification was completed, the emulsion was filtered and collected using a filter to obtain the microspheres, and washed with distilled water several times, then collected, added with a protective agent, and freeze-dried to obtain a brelasarzine sustained-release microsphere preparation.
[0199] The microspheres of the preparation were quantitatively determined by HPLC, and the encapsulation efficiency was 52% and the yield was 64%.
[0200] Comparative Formulations 7 and 8 were subjected to in vitro release testing according to the in vitro release testing method described in Test Example 1 of the present invention. The 24-hour burst release rates of both Comparative Formulations 7 and 8 exceeded 20%. Furthermore, the total cumulative release rate of Comparative Formulation 3 exceeded 95% after 21 days, failing to meet the one-month sustained release requirement.
[0201] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be determined by the appended claims.
Claims
1. A method for preparing sustained-release microspheres for injection, The following steps are involved: A) dissolving a biocompatible polymer material in an organic solvent to form an organic solution, adding a pharmaceutical active ingredient and dispersing the pharmaceutical active ingredient in the organic solution to obtain an oil phase; B) dissolving a surfactant in water to prepare an external aqueous phase; C) mixing and emulsifying the oil phase and the external aqueous phase to obtain a mixed emulsion; D) solidifying and drying the mixed emulsion to obtain sustained-release microspheres containing the active pharmaceutical ingredient.
2. The method according to claim 1, Features: The active pharmaceutical ingredient is partially dissolved in the organic solution and partially forms insoluble solid particles, and the prepared oil phase is a suspension containing the solid particles of the active pharmaceutical ingredient.
3. The method according to claim 1, Features: The mass percentage of the active pharmaceutical ingredient to the organic solvent is 2.7-22.2 wt %, and the mass percentage of the biocompatible polymer material to the oil phase is 9.6-40 wt %.
4. The method according to claim 3, Features: The mass percentage concentration of the surfactant in the external water phase is 0.1-5.0 wt %.
5. The method according to claim 4, Features: The ratio of the mass (g) of the organic solvent to the volume (mL) of the external aqueous phase is 1:10-1:
250.
6. The method according to claim 1, Features: The organic solvent is dichloromethane.
7. The method according to claim 1, Features: The active pharmaceutical ingredient is any one of the following: epiprazole and / or a pharmaceutically acceptable salt thereof, lurasidone and / or a pharmaceutically acceptable salt thereof, cariprazine and / or a pharmaceutically acceptable salt thereof, brelasarzine and / or a pharmaceutically acceptable salt thereof.
8. The method according to claim 1, Features: The biocompatible polymer material is one or a mixture of polylactic acid-glycolic acid copolymer (PLGA), polylactic acid (PLA), polyglycolide (PGA) and poly(vinyl acetate) (PCL).
9. The method according to claim 1, Features: The surfactant is one or a mixture of polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), carboxymethyl cellulose (CMC), hydroxyethyl cellulose (HEC), β-cyclodextrin, poloxamer 188, Pluronic F88, Pluronic F127, gelatin, glycine, lysine, histidine, arginine, aspartic acid, glutamic acid, tween.
10. The method according to claim 1, Features: In step D, the mixed emulsion is solidified into wet microspheres, a protective agent is added, and drying is performed.
11. The method according to claim 1, Features: The following steps are also included: After the mixed emulsion is obtained, the mixed emulsion is stirred, solidified, filtered, and washed with water to form wet microspheres, and a protective agent is added to the wet microspheres and then dried.
12. The method according to claim 10 or 11, Features: The protective agent is one or a mixture of polyethylene glycol (PEG), gelatin, glycerol, mannitol, sucrose, trehalose, lactose, glucose, propylene glycol, sorbitol, zinc chloride, zinc sulfate, zinc acetate and human serum albumin.
13. The method according to claim 10 or 11, Features: Other auxiliary materials are added at the same time as the protective agent, and the other auxiliary materials are surfactants and / or excipients.
14. A sustained-release microsphere for injection prepared according to the method of any one of claims 1 to 13.
Citation Information
Patent Citations
Method of preparing S / O / W of 5-fluorouracil biodegradable polymer microspheres
CN101549272A
Sustained release microsphere medicinal preparation using PHBHHx as carrier and method for preparing same
CN101708175A
Long-acting slow-release pharmaceutical preparation and preparation method thereof
CN107213136A
Tertiary amine pharmaceutical composition and industrial batch preparation method thereof
CN112367997A
Process for the production of microparticles using a water-immiscible organic solvent, and a sustained release formulation comprising said microparticles
IL141682B
Cited By
Brexpiprazole long-acting microsphere and preparation method thereof
CN119837834A
Gel for in-vivo cultivation of calculus bovis and preparation method thereof
CN120662284A
Microsphere-oil gel composite slow-release injection and preparation method thereof
CN122163577A
Method for preparing sustained-release microspheres using small-particle-size drug particles, and prepared microspheres
WO2026081528A1
